Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) announced that it plans to discontinue the ARMOR3-SV clinical trial, the company’s pivotal Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE